{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-046976","form_type":"8-K","ticker":null,"cik":"0001267813","company_name":"MARINUS PHARMACEUTICALS, INC.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.658420+00:00","generated_at":"2026-06-03T22:49:27.879807+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Marinus RAISE trial interim analysis fails early stopping criteria; Q1 ZTALMY revenue $7.4-7.6M","bullets":["DMC recommended continue RAISE; enrollment completed at ~100 patients; topline results summer 2024.","Q1 2024 preliminary ZTALMY net revenue $7.4-7.6 million; cash $113.3 million as of March 31.","TrustTSC enrollment expected mid-May; topline data on track for Q4 2024.","Cost reduction activities under review to extend cash runway beyond Q4 2024.","IV ganaxolone development for RSE to be reassessed after final RAISE results."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-046976","json":"https://secwatch.observer/filing/0001104659-24-046976.json","markdown":"https://secwatch.observer/filing/0001104659-24-046976.md","text":"https://secwatch.observer/filing/0001104659-24-046976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/0001104659-24-046976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/tm2411822d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:49:27.879807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b653a2ce380f94e766617ee2effca631bc33c8bf","claim":"MARINUS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue between $7.4 and $7.6 million.","evidence_excerpt":"Cost reduction activities to extend cash runway are under review and expected to be implemented Q2 2024 ZTALMY ® (ganaxolone) Q1 2024 preliminary net product revenue of between $7.4 and $7.6 million; preliminary unaudited cash, cash equivalents and short-term investments of $113.3 million as of March 31, 2024 RADNOR, Pa. – April 15, 2024 – Marinus","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/0001104659-24-046976-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"between $7.4 and $7.6 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}